口服组胺H1受体拮抗剂在儿童中合理应用的 临床实践指南计划书  

Rational use of oral H1 receptor antagonists in children:a clinical practice guideline protocol

作　　者：周鹏翔[1,2] 翟所迪 周薇[3] ZHOU Pengxiang;ZHAI Suodi;ZHOU Wei(Department of Pharmacy,Peking University Third Hospital,Beijing 100191,P.R.China;Institute for Drug Evaluation,Peking University Health Science Center,Beijing 100191,P.R.China;Department of Pediatrics,Peking University Third Hospital,Beijing 100191,P.R.China)

机构地区：[1]北京大学第三医院药剂科,北京100191 [2]北京大学医学部药物评价中心,北京100191 [3]北京大学第三医院儿科,北京100191

出　　处：《中国循证医学杂志》2021年第1期90-96,共7页Chinese Journal of Evidence-based Medicine

基　　金：国家科技重大专项项目(编号:2017ZX09304029-005-02)。

摘　　要：本指南计划书详细介绍《口服组胺H1受体拮抗剂在儿童中合理应用的临床实践指南》制订的各个关键环节的方法、流程和注意事项。参考《世界卫生组织指南制订手册》,按照指南制订的标准化流程进行指南项目组的筹建(包括指导委员会、指南专家组、指南秘书组、指南外审组和患者家属组)、指南注册(注册号:IPGRP-2020CN110)、临床问题的与结局指标的收集与确定、证据的检索、评价整合与利用、推荐意见的形成和外审、推荐意见的修订、指南的撰写与发布、指南的后效评价与更新等步骤,旨在为科学和循证制订临床指南提供纲要性和指导性的实施方案。The protocol of rational use of oral H1 receptor antagonists in children:a clinical practice guideline primarily introduces key methods,processes and precautions of the guideline to standardize and guarantee the formulation of this evidence-based guideline.Referring to the World Health Organization Guidelines Development Manual,the guideline will be conducted according to the following steps,which involves the establishment of project group;registration(IPGRP-2020CN110);declaration of interest and funding support;identification of the clinical issues and outcomes;evidence retrieval,assessment,synthesis and utilization;investigation of patients’preferences and values;development,external review and revision of recommendations;guideline release,dissemination and update.

关 键 词：组胺H1受体拮抗剂 变态反应性疾病 儿童 临床实践指南 计划书 

分 类 号：R969.3[医药卫生—药理学]